TABLE 1.
Characteristics of study subjects receiving alalevonadifloxacin (1,000 mg) every 12 h for 10 dosesa
| Sampling time (h)b | Sex of patients | Age (yr) | ht (cm) | wt (kg) | eCLCR (ml/min) | Total cell count in BAL fluid (cells/mm3) | Macrophages (%) |
|---|---|---|---|---|---|---|---|
| 2 | 2 M, 4 F | 39 ± 6 | 172 ± 7 | 78.3 ± 12.2 | 123 ± 24 | 106 ± 22 | 84 ± 8 |
| 4 | 3 M, 3 F | 37 ± 9 | 172 ± 10 | 74.6 ± 7.0 | 105 ± 13 | 163 ± 92 | 86 ± 6 |
| 6 | 4 M, 2 F | 31 ± 8 | 171 ± 9 | 70.5 ± 9.0 | 106 ± 20 | 96 ± 25 | 84 ± 7 |
| 8 | 6 M | 41 ± 12 | 175 ± 7 | 83.0 ± 9.6 | 119 ± 24 | 105 ± 35 | 85 ± 11 |
| 12 | 6 M | 36 ± 9 | 178 ± 6 | 85.7 ± 11.6 | 123 ± 26 | 118 ± 65 | 88 ± 6 |
a
Data are expressed as means ± 1 SD, except for the data on sex. Abbreviations: M, males; F, females; eCLCR, estimated creatinine clearance.
b
Six subjects were examined at each sampling time.